Upsher Smith Laboratories Patent-Cliff Exposure & CMS Drug Spending Portfolio

Upsher Smith Laboratories (Maple Grove, MN): 3 reconciled FDA prescription therapies, $15.8M 2024 CMS Part D & Medicaid spend, and $14,215 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterMaple Grove, MN
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2033-01-01
2024 CMS Total Public Spend$15.8M
2024 Medicare Part D Spend$10.9M
2024 Medicaid Spend$5.0M
California HCAI SB 17 FilingsSpecialty launch notice ($14,215 intro WAC)